Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma

摘要: BACKGROUND The study was undertaken to determine the safety and efficacy of monoclonal, antivascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women platinum-refractory ovarian cancer. METHODS A retrospective analysis who received a agent performed. Response determined by measurable disease or assessment serial cancer antigen (CA) 125 measurements. RESULTS Twenty-three patients were identified. The heavily pretreated median 7 prior regimens including 3 platinum regimens. regimen included cyclophosphamide 15 (65%), 5-fluorouracil (5-FU) 6 (26%), docetaxel 1 (4%), gemcitibine/liposomal doxorubicin (4%). Two (9%) developed chylous ascites during treatment. CTC Grade 4–5 toxicities occurred 4 (17%) subjects. Gastrointestinal perforation 2 patients. Measurable present 22. overall best response rate 35% all 8 partial responses (PRs). Stable found further 10 (44%) women, whereas progressive observed 5 (22%). time progression 5.6 months PR 2.3 subjects stable disease. Three (13%) experienced progression-free interval (PFI) >6 months. At last follow-up, (35%) had died disease, (65%) alive disease. CONCLUSIONS Combination therapy demonstrated activity cancer. perforations identified 9%. Despite toxicity regimen, prospective studies, particularly less patients, are warranted. Cancer 2006. © 2006 American Society.